Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27847925 | 0.98 | CDK8 (0.40) | CDK8ROCK1CHEK1AURKADAPK3 | |
| SCHEMBL26112141 | 0.82 | IMPDH2 (0.38) | CDK8ROCK1CHEK1AURKADAPK3 | |
| SCHEMBL29930920 | 0.76 | GPR119 (0.40) | — | |
| SCHEMBL3700594 | 0.74 | TSHR (0.39) | KDM4ETDP1MEN1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL28200481 | 0.73 | TSHR (0.38) | KDM4ETDP1MEN1ALDH1A1MAPT | |
| SCHEMBL28102813 | 0.70 | EGFR (0.37) | IMPDH2AR | |
| Isoquinoline SCHEMBL3099710 | 0.69 | KDM4E (0.50) | CDK8ROCK1CHEK1AURKADAPK3 | |
| SCHEMBL256355 | 0.69 | HASPIN (0.43) | GSK3BDYRK1AKDM4EMAPTPRKCZ | |
| Isoquinoline SCHEMBL2230386 | 0.68 | IMPDH2 (0.50) | CDK8ROCK1CHEK1AURKADAPK3 | |
| SCHEMBL14312993 | 0.67 | SLC22A12 (0.55) | SIRT3TDP1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | claimed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| WO-2024121048-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| EP-4003958-A1 | SYNTHESIS OF BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | Alkermes, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | CDK8 1219/4885ROCK1 13/4885CHEK1 3298/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | CDK8 1243/4885ROCK1 8/4885CHEK1 2969/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | CDK8 1243/4885ROCK1 8/4885CHEK1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.